Evidence map›Paper›PMID 39458971›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

In Vitro Evaluation of Pharmacokinetic Properties of Selected Dual COX-2 and 5-LOX Inhibitors.

Jelena Bošković, Vladimir Dobričić, Jelena Savić, Jelena Rupar, Mara Aleksić, Bojan Marković, Olivera Čudina

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Novel Pyridine-Based Thiazolyl-Hydrazone as a Promising Attenuator ofInternational journal of molecular sciences · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jelena BoškovićDepartment of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.
Vladimir DobričićDepartment of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.ORCID 0000-0002-5086-9017
Jelena SavićDepartment of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.
Jelena RuparDepartment of Physical Chemistry and Instrumental Methods, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.ORCID 0000-0001-5451-8516
Mara AleksićDepartment of Physical Chemistry and Instrumental Methods, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.ORCID 0000-0002-5332-7117
Bojan MarkovićDepartment of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.ORCID 0000-0002-3825-4394
Olivera ČudinaDepartment of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia.

Funding

Ministry of Science, Technological Development and Innovation of the Republic of Serbia 451-03-65/2024-03/200161 and 451-03-66/2024-03/200161Science Fund of the Republic of Serbia 7739840
6 · The paper itself

Abstract

Evaluation of pharmacokinetic properties is a significant step at the early stages of drug development. In this study, an in vitro evaluation of the pharmacokinetic properties of five newly synthesized compounds was performed. These compounds belong to N-hydroxyurea and hydroxamic acid derivatives and analogs of NSAIDs indomethacin, flurbiprofen, diclofenac, ibuprofen, and naproxen (compounds

Indexed as

dual COX-2 and 5-LOX inhibitorsHSA binding affinitymicrosomal stabilityN-hydroxyurea and hydroxamic acidpassive gastrointestinal absorption

Identifiers

PMID39458971
PMCPMC11510591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.